Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 4, 2022
Principal Executive Offices: Cambridge, Massachusetts
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a regulatory event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
The U.S. Food and Drug Administration (FDA) extended the review timeline for the New Drug Application (NDA) for vutrisiran by 3 months. The updated Prescription Drug User Fee Act (PDUFA) action date is now July 14, 2022.
Guidance, Outlook, and Management Commentary
- Reason for Delay: The extension allows the FDA to review an amendment to the regulatory submission addressing a pending inspection classification at a third-party secondary packaging and labeling facility.
- Resolution: A new secondary packaging and labeling facility has been identified and incorporated into the existing submission.
- Clinical Data: No additional clinical data have been requested by the FDA.
- Inspection Observations: No inspection observations were directly related to vutrisiran.
Investor Verification Checklist
- Verify the new PDUFA action date of July 14, 2022, for vutrisiran.
- Confirm that the delay is administrative (facility inspection) and not related to clinical efficacy or safety data.
- Review the attached press release (Exhibit 99.1) for further details on the facility transition.